SCHEMBL13968366

SCHEMBL13968366

O=Cc1ccc(Nc2nc(-c3ccc(N=O)cc3)nc3ccccc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 10/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
PDE5A O76074 3/20 0.56
ABCC1 P33527 1/20 0.56
MAPT P10636 3/20 0.55
TP53 P04637 2/20 0.55
GAA P10253 2/20 0.55
LMNA P02545 1/20 0.55
SIRT5 Q9NXA8 1/20 0.55
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
POLB P06746 2/20 0.53
TGFBR1 P36897 1/20 0.53
MAPK14 Q16539 1/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KDM1A O60341 2/20 0.53
GBA1 P04062 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8096436 0.86 ABCG2 (0.76) ABCG2MEN1KMT2APDE5AABCC1
SCHEMBL13969181 0.86 ABCG2 (0.76) ABCG2MEN1KMT2APDE5AABCC1
SCHEMBL13969179 0.76 MEN1 (0.72) ABCG2MEN1KMT2AMAPTTP53
SCHEMBL8091996 0.76 ABCG2 (0.68) ABCG2MEN1KMT2APDE5AABCC1
SCHEMBL1063103 0.75 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AABCC1
SCHEMBL22201364 0.74 ABCG2 (0.94) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL4868573 0.74 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AABCC1
SCHEMBL14262835 0.73 ABCG2 (0.82) ABCG2MEN1KMT2APDE5AABCC1
SCHEMBL15977132 0.72 KDM4E (0.76) ABCG2MEN1KMT2APDE5AABCC1
SCHEMBL13945468 0.72 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 ABCG2 602/4885MEN1 4478/4885KMT2A 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.